Funding to advance machine learning in dualase-based therapies
- Grant awarded to Specific Biologics and Western University
- Funding will support development of a machine learning platform
- Aim is to enhance dualase-based therapeutic solutions
Genome Canada and Ontario Genomics have awarded a grant of $1.8 million to Specific Biologics and Western University. This funding is intended to support the development of a machine learning platform aimed at accelerating the creation of dualase-based therapeutics. These therapeutics are designed to improve treatment outcomes in various diseases.
The grant will facilitate the integration of advanced machine learning methodologies to enhance the efficiency and effectiveness of developing dualase-based therapies. This innovative approach aims to streamline the therapeutic development process, ultimately benefiting patients in need. Both Genome Canada and Ontario Genomics emphasize the importance of using cutting-edge technology to advance health research.
As dualase-based therapeutics show promise in medical applications, the collaboration between Specific Biologics and Western University signifies a significant step forward. The investment in machine learning could lead to breakthroughs that enhance therapeutic strategies, aligning with ongoing efforts to improve health care delivery and outcomes.
